Skip to main
VYGR

Voyager Therapeutics (VYGR) Stock Forecast & Price Target

Voyager Therapeutics (VYGR) Analyst Ratings

Based on 5 analyst ratings
Buy
Strong Buy 40%
Buy 60%
Hold 0%
Sell 0%
Strong Sell 0%

Bulls say

Voyager Therapeutics Inc is positioned positively due to its robust TRACER platform, which is expected to generate increasing revenues from collaborations advancing to clinical trials in the 2030s. The company's innovative approach in gene therapy demonstrates significant early clinical results, particularly with VY1706, which showed a reduction in tau messenger RNA by up to 73% in non-human primates, indicating promising efficacy. Furthermore, recent preclinical data suggests that Voyager's NeuroShuttle technology offers enhanced durability and safety advantages over existing therapies, strengthening its potential in the competitive neurology market.

Bears say

The financial outlook for Voyager Therapeutics Inc appears unfavorable due to significant operational losses that have led to dwindling cash reserves, raising concerns about the company's ability to fund ongoing research and development efforts. Additionally, the lack of substantial progress in advancing its therapeutic pipeline and the increasing competition in the gene therapy space pose risks to future revenue generation and market positioning. These factors, combined with the uncertainty surrounding clinical trial outcomes, contribute to a negative assessment of the company's financial viability and growth prospects.

Voyager Therapeutics (VYGR) has been analyzed by 5 analysts, with a consensus rating of Buy. 40% of analysts recommend a Strong Buy, 60% recommend Buy, 0% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Voyager Therapeutics and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Voyager Therapeutics (VYGR) Forecast

Analysts have given Voyager Therapeutics (VYGR) a Buy based on their latest research and market trends.

According to 5 analysts, Voyager Therapeutics (VYGR) has a Buy consensus rating as of Dec 30, 2025. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $12.15, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $12.15, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Voyager Therapeutics (VYGR)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.